Patents by Inventor John Rodney Woodrow

John Rodney Woodrow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9139611
    Abstract: Protein particles are prepared by causing or allowing protein molecules dispersed in a liquid medium at a concentration of 8 mg.mL?1 or greater to react in the presence of a zero-length crosslinker, so as to produce protein particles comprising protein molecules that are covalently bonded together. The protein particles may be produced with sizes in the sub-micron range with closely defined sizes and size distributions. The particles have applications in many fields, but are useful inter alia for the delivery of therapeutic agents and other agents, eg imaging contrast agents, to the body.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: September 22, 2015
    Assignees: NOVOZYMES BIOPHARMA DK A/S, UPPERTON LIMITED
    Inventors: Richard Alan Johnson, John Rodney Woodrow
  • Patent number: 9029102
    Abstract: A process is provided for the preparation of a highly pure albumin solution the process comprising subjecting albumin (preferably expressed and secreted by transformed yeast) to a series of chromatographic steps. Preferably, the process comprises the steps of positive mode cation exchange chromatography, positive mode anion exchange chromatography, positive mode affinity chromatography, negative mode affinity chromatography (preferably using immobilized aminophenylboronic acid), negative mode cation exchange chromatography, and negative or positive mode anion exchange chromatography. A process for reducing the level of nickel in an albumin solution is also disclosed, as is a recombinant albumin coding sequence comprising two or more in-frame translation stop codons.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: May 12, 2015
    Assignee: Novozymes Biopharma DK A/S
    Inventors: Hendrik Van Urk, Philip Harvey Morton, Andrew John Cartwright, Jason Cameron, David James Ballance, Michael Gaston Joseph Grandgeorge, Stephen Berezenko, John Rodney Woodrow, Jean-Luc Bernard Veron
  • Publication number: 20150056654
    Abstract: A process is provided for the preparation of a highly pure albumin solution the process comprising subjecting albumin (preferably expressed and secreted by transformed yeast) to a series of chromatographic steps. Preferably, the process comprises the steps of positive mode cation exchange chromatography, positive mode anion exchange chromatography, positive mode affinity chromatography, negative mode affinity chromatography (preferably using immobilised aminophenylboronic acid), negative mode cation exchange chromatography, and negative or positive mode anion exchange chromatography. A process for reducing the level of nickel in an albumin solution is also disclosed, as is a recombinant albumin coding sequence comprising two or more in-frame translation stop codons.
    Type: Application
    Filed: July 14, 2014
    Publication date: February 26, 2015
    Inventors: Hendrik Van Urk, David John Mead, Philip Harvey Morton, Andrew John Cartwright, Jason Cameron, David James Ballance, Michael Gaston Grandgeorge, Stephen Berezenko, John Rodney Woodrow, Darrell Sleep, Jean-luc Bernard Veron
  • Publication number: 20110301329
    Abstract: A process is provided for the preparation of a highly pure albumin solution the process comprising subjecting albumin (preferably expressed and secreted by transformed yeast) to a series of chromatographic steps. Preferably, the process comprises the steps of positive mode cation exchange chromatography, positive mode anion exchange chromatography, positive mode affinity chromatography, negative mode affinity chromatography (preferably using immobilised aminophenylboronic acid), negative mode cation exchange chromatography, and negative or positive mode anion exchange chromatography. A process for reducing the level of nickel in an albumin solution is also disclosed, as is a recombinant albumin coding sequence comprising two or more in-frame translation stop codons.
    Type: Application
    Filed: July 1, 2011
    Publication date: December 8, 2011
    Applicant: Novozymes Biopharma DK A/S
    Inventors: Hendrik Van Urk, David John Mead, Philip Harvey Morton, Andrew John Cartwright, Jason Cameron, David James Ballance, Michel Gaston Joseph Grandgeorge, Stephen Berezenko, John Rodney Woodrow, Darrell Sleep, Jean-Luc Bernard Veron
  • Patent number: 7993877
    Abstract: A process is provided for the preparation of a highly pure recombinant albumin solution having a nickel ion content of less than 100 ng per gram of albumin. The process comprises subjecting a recombinant albumin to a series of chromatography, concentration, and diafiltration steps.
    Type: Grant
    Filed: September 9, 2008
    Date of Patent: August 9, 2011
    Assignee: Novozymes Biopharma DK A/S
    Inventors: Hendrik Van Urk, David John Mead, Philip Harvey Morton, Andrew John Cartwright, Jason Cameron, David James Ballance, Michel Gaston Joseph Grandgeorge, Stephen Berezenko, John Rodney Woodrow, Darrell Sleep, Jean-Luc Bernard Veron
  • Publication number: 20110142762
    Abstract: This invention relates to the delivery of agents to the body. One particular class of such agents are contrast agents useful in medical imaging techniques. The agents may be metals useful as contrast agents in magnetic resonance imaging (MRI), or in nuclear imaging, including positron emission tomography (PET), or as therapeutic agents in radiotherapy. The agents may alternatively be contrast agents useful in X-ray imaging. The invention also relates to methods by which agents for delivery to the body can be coupled to carriers and to targeting moieties effective to direct the agent to a specific locus within the body.
    Type: Application
    Filed: January 19, 2011
    Publication date: June 16, 2011
    Applicants: Novozymes Biopharma DK A/S, Upperton Limited
    Inventor: John Rodney Woodrow
  • Patent number: 7601515
    Abstract: A process is provided for the preparation of albumin from a yeast culture medium which has extremely low levels of or is essentially free of colorants, metal ions, human proteins, host proteins, fragments of albumin, polymers or aggregates of albumin and viruses, and which is essentially non-glycated, relatively high in free thiol and with an intact C-terminus. The process comprises separating the yeast from the culture medium to yield an albumin solution; subjecting the albumin solution to positive mode cation exchange, affinity, and positive mode anion exchange chromatography; and concentrating and formulating the albumin with sodium octanoate and sodium chloride.
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: October 13, 2009
    Assignee: Novozymes Biopharma UK Limited
    Inventors: Andrew Robert Goodey, Darell Sleep, Hendrik Van Urk, Stephen Berezenko, John Rodney Woodrow, Richard Alan Johnson, Patricia Carol Wood, Stephen James Burton, Alan Victor Quirk
  • Publication number: 20090197316
    Abstract: Protein particles are prepared by causing or allowing protein molecules dispersed in a liquid medium at a concentration of 8 mg.mL-1 or greater to react in the presence of a zero-length crosslinker, so as to produce protein particles comprising protein molecules that are covalently bonded together. The protein particles may be produced with sizes in the sub-micron range with closely defined sizes and size distributions. The particles have applications in many fields, but are useful inter alia for the delivery of therapeutic agents and other agents, eg imaging contrast agents, to the body.
    Type: Application
    Filed: July 13, 2007
    Publication date: August 6, 2009
    Applicants: Novozymes Biopharma UK Limited, Upperton Limited
    Inventors: Richard Alan Johnson, John Rodney Woodrow
  • Publication number: 20090171070
    Abstract: A process is provided for the preparation of a highly pure recombinant albumin solution having a nickel ion content of less than 100 ng per gram of albumin. The process comprises subjecting a recombinant albumin to a series of chromatography, concentration, and diafiltration steps.
    Type: Application
    Filed: September 9, 2008
    Publication date: July 2, 2009
    Applicant: NOVOZYMES BIOPHARMA UK LIMITED
    Inventors: Hendrik Van Urk, David John Mead, Philip Harvey Morton, Andrew John Cartwright, Jason Cameron, David James Ballance, Michel Gaston Joseph Grandgeorge, Stephen Berezenko, John Rodney Woodrow, Darrell Sleep, Jean-Luc Bernard Veron
  • Patent number: 7223561
    Abstract: A process is provided for the preparation of albumin which has extremely low levels of or is essentially free of colorants, metal ions, human proteins, host proteins, fragments of albumin, polymers or aggregates of albumin and viruses, and which is essentially non-glycated, relatively high in free thiol and with an intact C-terminus. The process comprises passing albumin (preferably expressed and secreted by transformed yeast) through positive mode cation exchange and then positive mode anion exchange chromatography. Other steps may also be employed, ultrafiltration, gel permeation chromatography, affinity chromatography binding the albumin by using blue dyes) and affinity chromatography binding contaminants by using an aminophenylboronic acid resin. Elution of albumin, with a compound having affinity for albumin, from a material having no specific affinity for albumin is also disclosed, as is removal of ammonium ions with a counter-ion.
    Type: Grant
    Filed: June 22, 2004
    Date of Patent: May 29, 2007
    Assignee: Novozymes Delta, Limited
    Inventors: Andrew Robert Goodey, Darell Sleep, Hendrik Van Urk, Stephen Berezenko, John Rodney Woodrow, Richard Alan Johnson, Patricia Carol Wood, Stephen James Burton, Alan Victor Quirk
  • Patent number: 6638740
    Abstract: The present invention relates to a process for purifying the protein human serum albumin extracted from serum or recombinant human albumin produced by transforming a microorganism with a nucleotide coding sequence encoding the amino acid sequence of human serum albumin. The present invention provides highly purified albumin.
    Type: Grant
    Filed: February 24, 1999
    Date of Patent: October 28, 2003
    Assignee: Delta Biotechnology Ltd.
    Inventors: Andrew Robert Goodey, Darrell Sleep, Hendrik Van Urk, Stephen Berezenko, John Rodney Woodrow, Richard Alan Johnson, Patricia Carol Wood, Stephen James Burton, Alan Victor Quirk
  • Publication number: 20030187226
    Abstract: A process is provided for the preparation of albumin which has extremely low levels of or is essentially free of colorants, metal ions, human proteins, host proteins, fragments of albumin, polymers or aggregates of albumin and viruses, and which is essentially non-glycated, relatively high in free thiol and with an intact C-terminus. The process comprises passing albumin (preferably expressed and secreted by transformed yeast) through positive mode cation exchange and then positive mode anion exchange chromatography. Other steps may also be employed, for example ultrafiltration, gel permeation chromatography, affinity chromatography binding the albumin (for example using blue dyes) and affinity chromatography binding contaminants (for example using an aminophenylboronic acid resin). Elution of albumin, with a compound having affinity for albumin, from a material having no specific affinity for albumin is also disclosed, as is removal of ammonium ions with a counter-ion.
    Type: Application
    Filed: November 21, 2002
    Publication date: October 2, 2003
    Inventors: Andrew Robert Goodey, Darrell Sleep, Hendrik Van Urk, Stephen Berezenko, John Rodney Woodrow, Richard Alan Johnson, Patricia Carol Wood, Stephen James Burton, Alan Victor Quirk